Revisiting the role of Wnt/β-catenin signaling in prostate cancer

Publication date: Available online 9 February 2017
Source:Molecular and Cellular Endocrinology
Author(s): Jeffrey A. Schneider, Susan K. Logan
The androgen receptor (AR) is a widely accepted therapeutic target in prostate cancer and multiple studies indicate that the AR and Wnt/β-catenin pathways intersect. Recent genome-wide analysis of prostate cancer metastases illustrate the importance of the Wnt/β-catenin pathway in prostate cancer and compel us to reexamine the interaction of the AR and Wnt/β-catenin signaling pathways. This review includes newer areas of interest such as non-canonical Wnt signaling and the role of Wnts in prostate cancer stem cells. The effort to develop Wnt modulating therapeutics, both biologics and small molecules, is also discussed.



http://ift.tt/2kPImiH